Search | OpenScholar

Search results

374 results found

Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005;11:469-471.

Publication: Journal Article

Sullivan, KL, RA Hauser, ED Louis, G Chari, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Generalized Dystonia. Parkinsonism Relat Disord 2005;11:469-471.”. Parkinsonism Relat Disord.

Parkinson's disease home diary: further validation and implications for clinical trials. Movement Disorders 2004;19:1409-1413.

Publication: Journal Article

Hauser, RA, F Deckers, and P Lehert. 2004. “Parkinson’s Disease Home Diary: Further Validation and Implications for Clinical Trials. Movement Disorders 2004;19:1409-1413.”. Movement Disorders.

Sleep attacks and dopamine agonists for Parkinson’s disease: What is currently known? CNS Drugs 2003;17:593-600.

Publication: Journal Article

Zesiewicz, TA, and RA Hauser. 2003. “Sleep Attacks and Dopamine Agonists for Parkinson’s Disease: What Is Currently Known? CNS Drugs 2003;17:593-600.”. CNS Drugs.

Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93-101.

Publication: Journal Article

Whone, AL, RL Warrs, AJ Stoessl, M Davis, S Reske, C Nahmias, AE Lang, et al. 2003. “Slower Progression of Parkinson’s Disease With Ropinirole versus Levodopa: The REAL-PET Study. Ann Neurol. 2003;54:93-101.”. 2003.

Initial management of Parkinson’s disease in a Florida community. J Applied Research 2004;4:95-98.

Publication: Journal Article

Zesiewicz, TA, SN Carter, KL Sullican, JS Staffetti, PB Dunne, and RA Hauser. 2003. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.

Videotape demonstration of a sensory trick in writer’s cramp. Movement Disorders 2002;17:427.

Publication: Journal Article

Hauser, RA, and D Burke. 2002. “Videotape Demonstration of a Sensory Trick in Writer’s Cramp. Movement Disorders 2002;17:427.”. Movement Disorders.

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Movement Disorders 2002;17:961-968.

Publication: Journal Article

Hauser, RA, and NH Holford. 2002. “Quantitative Description of Loss of Clinical Benefit Following Withdrawal of Levodopa-Carbidopa and Bromocriptine in Early Parkinson’s Disease. Movement Disorders 2002;17:961-968.”. Movement Disorders.

Contact Us

Page

Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Movement Disorders 1994;9:467-469.

Publication: Journal Article

Hauser, RA, and R Trehan. 1994. “Initial Experience With Electroconvulsive Therapy for Progressive Supranuclear Palsy. Movement Disorders 1994;9:467-469.”. Movement Disorders.

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.

Publication: Journal Article

Woodward, WR, CW Olanow, RM Beckner, RA Hauser, LL Gauger, JM Cedarbaum, and J Nutt. 1993. “The Effect of L-Dopa Infusions With and Without Phenylalanine Challenges in Parkinsonian Patients: Plasma and Ventricular CSF L-Dopa Levels and Clinical Responses. Neurology 1993;43:1704-1708.”. Neurology.